CA3081757C - Traitement du cancer utilisant une immunite antimicrobienne preexistante - Google Patents

Traitement du cancer utilisant une immunite antimicrobienne preexistante

Info

Publication number
CA3081757C
CA3081757C CA3081757A CA3081757A CA3081757C CA 3081757 C CA3081757 C CA 3081757C CA 3081757 A CA3081757 A CA 3081757A CA 3081757 A CA3081757 A CA 3081757A CA 3081757 C CA3081757 C CA 3081757C
Authority
CA
Canada
Prior art keywords
mhc
antigen
cancer
immune response
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3081757A
Other languages
English (en)
Other versions
CA3081757A1 (fr
Inventor
John T. Schiller
Nicolas CUBURU
Douglas R. Lowy
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority claimed from PCT/US2018/059384 external-priority patent/WO2019090304A1/fr
Publication of CA3081757A1 publication Critical patent/CA3081757A1/fr
Application granted granted Critical
Publication of CA3081757C publication Critical patent/CA3081757C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des méthodes, des compositions et des kits pour rediriger une réponse immunitaire préexistante chez un individu de façon à réduire ou à stabiliser un cancer chez ledit individu.
CA3081757A 2017-11-06 2018-11-06 Traitement du cancer utilisant une immunite antimicrobienne preexistante Active CA3081757C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582097P 2017-11-06 2017-11-06
US62/582,097 2017-11-06
PCT/US2018/059384 WO2019090304A1 (fr) 2017-11-06 2018-11-06 Traitement du cancer utilisant une immunité antimicrobienne préexistante

Publications (2)

Publication Number Publication Date
CA3081757A1 CA3081757A1 (fr) 2019-05-09
CA3081757C true CA3081757C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
US20230330207A1 (en) Cancer treatment utilizing pre-existing microbial immunity
Jabbari et al. Secondary memory CD8+ T cells are more protective but slower to acquire a central–memory phenotype
JP2022068348A (ja) がんに対する組合せ療法
KR101689210B1 (ko) 백신 조성물 및 방법
Agallou et al. Identification of BALB/c immune markers correlated with a partial protection to Leishmania infantum after vaccination with a rationally designed multi-epitope cysteine protease a peptide-based nanovaccine
Chua et al. The use of a TLR2 agonist‐based adjuvant for enhancing effector and memory CD8 T‐cell responses
Wells et al. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity
AU2018274961A1 (en) Improved human herpesvirus immunotherapy
Moeini et al. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine
Zong et al. Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects
Ko et al. Potentiation of Th1-type immune responses to Mycobacterium tuberculosis antigens in mice by cationic liposomes combined with de-O-acylated lipooligosaccharide
CN104853764A (zh) 用于预防和治疗癌症的msi-特异性移码肽(fsp)
CA3081757C (fr) Traitement du cancer utilisant une immunite antimicrobienne preexistante
Locy et al. Dendritic cells: the tools for cancer treatment
US20230132140A1 (en) Method of treating cancer
Zhu et al. A therapeutic multi-epitope protein vaccine targeting HPV16 E6 E7 elicits potent tumor regression and cytotoxic immune responses
Cui et al. CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly (I: C)-adjuvanted MHC I-restricted peptide epitope
Behboudi et al. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
Gandhapudi et al. Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice. Viruses. 2023; 15 (2): 432
Sin MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model
Lu et al. Co-immunization with IFI35 enhances the therapeutic effect of an adenovirus vaccine against renal carcinoma
Indrová et al. NK1. 1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours
López-Gómez et al. Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2
CN120981242A (zh) 人乳头瘤病毒、水痘-带状疱疹病毒和狂犬病病毒抗原及其在癌症免疫疗法中的用途
Granadillo et al. Center for Genetic Engineering and Biotechnology. PO Box 6162, Cubanacan, Playa, Havana 10600, Cuba.